Navigation Links
Colony in Medical Technology

Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens

... broiler chickens were housed in 8' X 8' colony houses. Twenty birds from each colony were identified and infected with a full ... infected birds were reintroduced to their colony after which time ...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting

... Immunological effects and clinical outcomes in patients with high-risk melanoma given adjuvant therapy with granulocyte-macrophage colony stimulating factor (GM-CSF, sargramostim) Lead investigator: Lynn Spitler, Northern California Melanoma Center, Saint Mary's Medical ...

Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet Receives Milestone Payment for Filing of the First Clinical Trial Application for MT203

... 1 clinical trial for the treatment of patients with cancer. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

... MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet Key Events for 2009

... which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet Expands Committed Equity Financing Facility to $75 Million

... which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, ...

Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas

... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program

... a week for 24 weeks. In addition, some patients in the program were also treated with other agents including aerosol recombinant granulocyte monocyte colony stimulating factor (GM-CSF) an immune stimulating agent (n=20), ifosfamide (n=4), and/or gemcitabine (n=2). Results to date are as follows: -- ...

Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors

... a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market

... cell) in the blood is too low - is a serious side effect of cancer chemotherapy and can prevent the treatment from being successful. Granulocyte colony stimulating factor (G-CSF) is a human protein that can reverse neutropenia by initiating the production of neutrophils. Recombinant forms of the ...

Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future

... with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid ...

JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients

... Mayo clinic said: "In ex vivo studies, we have seen encouraging preliminary results with Cytopia's compounds including the inhibition of erythroid colony growth from PV patients harboring the JAK2 V617F mutation." Cytopia's Research Director Dr Chris Burns stated: "This data is important validation ...

Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer

... non patient-specific investigational therapeutics comprised of whole tumor cells that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and then irradiated for safety. GVAX is designed to be administered through intradermal ...

Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF

... on the pharmacokinetic properties of MAXY-G34 and the mobilization of CD34+ stem cells. About MAXY-G34 MAXY-G34 is a novel pegylated granulocyte colony stimulating factor (PEG-GCSF) designed to treat chemotherapy-induced neutropenia. Preclinical and Phase I studies show MAXY-G34 to have novel and ...

Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2

... including: - Reduction in spleen size of 33 to 100% in five of six patients evaluated - Reduction in erythropoietin-independent colony formation of up to 39% and up to 100% in two patients evaluated -- Relief of constitutional symptoms, including pruritus, fatigue, back ...

PROCRIT(R) (Epoetin Alfa) Data to be Presented at American Society of Hematology Annual Meeting

... 1990 to 2006 in transfusion-dependent MDS patients (n=578) treated with Epoetin alfa plus or minus granulocyte and granulocyte-macrophage colony stimulating factors (G/GM-CSF) assessed the efficacy of Epoetin alfa in achieving transfusion independence in transfusion-dependent MDS ...

MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis

... in the first Phase 1 clinical trial of CAM- 3001, a fully human monoclonal antibody (MAb) targeting the alpha subunit of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR). The study is designed to evaluate the safety and tolerability of single doses of CAM-3001 in patients with ...

Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria

... Infections (E-1616, 12:15 p.m. CDT) -- Comparative Intracellular Activity of 10 Anti-Staphylococcal Antibiotics (AABs) Against a Stable Small colony Variant (SCV) of S. aureus in a Model of Human THP-1 Macrophages (A-1437, 1:15 p.m. CDT) About Oritavancin Oritavancin is a novel ...

Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche

... IAPV is a significant marker for CCD." "Unbiased 454 Sequencing technology enabled us to rapidly assemble a comprehensive inventory of microflora in colony Collapse Disorder (CCD) and non-CCD populations, and provided the sequence information needed to identify candidate pathogens," stated Dr. Lipkin. ...

Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study

... At day 21, the catheters were challenged with an inoculum of one million colony forming units of methicillin-resistant staph aurius (MRSA). The untreated control catheter had 30,000 bacterial colony forming units (CFUs) adhered to the catheter surface while the Ceragenin ...

Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response

... immunotherapy for prostate cancer is comprised of two prostate cancer cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and irradiated for safety. GVAX cancer immunotherapy for prostate cancer is being developed as a ...

VioQuest Pharmaceuticals Announces Data Presentation for Its Akt Inhibitor VQD-002, at American Association for Cancer Research Annual Meeting

... PCas and can induce cell death of PCas that express functional p53. In this study, we found that roscovitine can inhibit cell growth, reduce colony formation and induce apoptosis in PC3 and PC3-M cells that are p53 negative, when co-cultured with either LY294002 (LY) or Triciribine (also known ...

Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis

... symptoms using the CFQ-R questionnaire. Aztreonam lysine for inhalation was also associated with significantly greater reductions in P. aeruginosa colony forming units (a measure of the amount of bacteria present in the lungs) at 28 days compared with placebo. Pseudomonas sensitivity as measured by ...

Telomerase Presentations at the AACR 2007 Annual Meeting

... on telomerase activity in myeloma stem cells. The Johns Hopkins team demonstrated that Geron's telomerase inhibitor, GRN163L, blocked growth and colony formation in both the stem and differentiated subpopulations of myeloma cells. In these studies, no other compounds have been shown to be as active ...

News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics

... immunization strategy uses Rexin-G in combination with Reximmune-C(TM) a tumor-targeted expression vector bearing a granulocyte macrophage colony stimulating factor (GM-CSF) gene. The intent of this two-step approach is to bring a complement of cells involved in humoral and cell-mediated ...
Other Contents
(Date:4/22/2014)... 2014 Scientists from the Florida campus of The ... that plays a critical but previously unknown role in ... showed a novel role for a protein known as ... eLife , a publisher supported by the Howard ... Wellcome Trust. , "This is a critical building block ...
(Date:4/22/2014)... nanotechnology expert will present a poster titled ... 7th International Nanotoxicology Congress to be held ... Monita Sharma will outline a strategy consistent with the ... " Toxicity Testing in the 21st Century: A Vision ... methods involving human cells and cell lines for mechanistic ...
(Date:4/22/2014)... Experimental Biology (FASEB) has released updated factsheets ... the National Institutes of Health (NIH) benefits each of ... pleased to make these factsheets available to help citizens ... state," said FASEB President, Margaret K. Offermann, MD, PhD. ... research funding, investing $29.2 billion in FY 2013 in ...
Breaking Biology News(10 mins):Scientists identify critical new protein complex involved in learning and memory 2
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... among women using a newer method of planned sterilization ... over a 10-year period than using the more commonly ... University and UC Davis has found. , Published ... the study found the higher risk of pregnancy with ... Essure. , "This study provides essential information for ...
(Date:4/22/2014)... mice and rabbits, Johns Hopkins scientists have found a ... successfully preventing the development of atherosclerosis, the main cause ... of death among humans. The condition develops when fat ... stiff, narrowed and hardened, greatly reducing their ability to ... brain. , In a series of experiments, described April ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4
Other TagsOther Tags